In re Zoloft Litigation


(3rd Cir., filed October 18, 2016): Arguing that an expert cannot premise a causation analysis on a single statistically-significant association when the larger body of epidemiological studies fails to find any such association.  Also, arguing that an expert cannot massage the data with after-the-fact analyses to create associations that were not found by the statistical methodologies originally selected by the scientists who performed the study.  Trial court judges must act as gatekeepers over the reliability of expert testimony, carefully evaluating whether such testimony is based on sound scientific principles or is simply bought-and-paid for “junk science.”

Court ruled in favor of ATRA's position

Status: On June 2, 2017, the Third Circuit ruled in favor of ATRA’s position.  The Court held that the lower court did not abuse its discretion when it excluded the expert witness’s testimony. 

Latest News

View all news

SCOTUS Should Affirm Federal Law Supremacy With FDA Authority Case

The U.S. Supreme Court has a chance to rein in state court rulings that impose liability on pharmaceutical companies that go beyond, and even contradict, the federal regulatory process of the FDA, according to Tiger Joyce, president of the American Tort Reform Association. He explains why it is imperative the high court review a case involving Janssen Pharmaceuticals.